Cynthia Kosloff
About
In The Last Decade
Cynthia Kosloff
19 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 86
- Pulmonary and Respiratory Medicine 1.6k
- Surgery 785
- Rheumatology 688
- Oncology 679
- Pathology and Forensic Medicine 619
Countries citing papers authored by Cynthia Kosloff
This map shows the geographic impact of Cynthia Kosloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Kosloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Kosloff more than expected).
Fields of papers citing papers by Cynthia Kosloff
This network shows the impact of papers produced by Cynthia Kosloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Kosloff. The network helps show where Cynthia Kosloff may publish in the future.
Co-authorship network of co-authors of Cynthia Kosloff
This figure shows the co-authorship network connecting the top 25 collaborators of Cynthia Kosloff. A scholar is included among the top collaborators of Cynthia Kosloff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cynthia Kosloff. Cynthia Kosloff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 202 | |
| 2 | 6 | |
| 3 | Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy breakdown → | 862 |
| 4 | Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. | 17 |
| 5 | 14 | |
| 6 | 123 | |
| 7 | Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). | 14 |
| 8 | 10 | |
| 9 | 236 | |
| 10 | Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). | 25 |
| 11 | 33 | |
| 12 | 55 | |
| 13 | 41 | |
| 14 | Multidisciplinary treatment of embryonal rhabdomyosarcoma in children: a progress report. | 16 |
| 15 | Multidisciplinary treatment of advanced stages of embryonal rhabdomyosarcoma in children. | 22 |
| 16 | 291 | |
| 17 | 49 | |
| 18 | Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery breakdown → | 445 |
| 19 | 271 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.